How many insider trades does FilingIQ track for DNTH?

FilingIQ tracks 93 Form 4 insider transactions for DNTH (Dianthus Therapeutics, Inc. /DE/), covering filings from Sep 12, 2023 onwards. 55 of those were filed in the last 90 days.

Are DNTH insiders net buyers or net sellers?

Across the full Form 4 history for DNTH, 7 transactions (8%) were open-market purchases and 29 (31%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does DNTH insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is DNTH in?

Dianthus Therapeutics, Inc. /DE/ (DNTH) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $2.08B.

DNTH insider trading

Healthcare

Dianthus Therapeutics, Inc. /DE/ — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

8% / 31%

Market cap

$2.08B

About Dianthus Therapeutics, Inc. /DE/

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. The company's lead novel and proprietary monoclonal antibody product candidate includes DNTH103, a human monoclonal immunoglobulin G4 with picomolar that binds the active form of C1s, which is in clinical-stage trials for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

Company website: dianthustx.com

DNTH insider activity at a glance

FilingIQ has scored 93 insider transactions for DNTH since Sep 12, 2023. The most recent filing in our index is dated May 8, 2026.

Across the full history, 7 open-market purchases and 29 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on DNTH insider trades is 60.0/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live DNTH trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for DNTH?: FilingIQ tracks 93 Form 4 insider transactions for DNTH (Dianthus Therapeutics, Inc. /DE/), covering filings from Sep 12, 2023 onwards. 55 of those were filed in the last 90 days.
Are DNTH insiders net buyers or net sellers?: Across the full Form 4 history for DNTH, 7 transactions (8%) were open-market purchases and 29 (31%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does DNTH insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is DNTH in?: Dianthus Therapeutics, Inc. /DE/ (DNTH) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $2.08B.

Methodology & sources

Every DNTH insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.